{"id":2890,"date":"2024-06-12T09:53:00","date_gmt":"2024-06-12T09:53:00","guid":{"rendered":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/?post_type=press_release&p=2890"},"modified":"2024-06-26T09:57:34","modified_gmt":"2024-06-26T09:57:34","slug":"ksq-therapeutics-announces-first-patient-dosed-in-clinical-development-program-for-ksq-001ex-a-crispr-cas9-engineered-tumor-infiltrating-lymphocyte-etil-therapy","status":"publish","type":"press_release","link":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/press-releases\/ksq-therapeutics-announces-first-patient-dosed-in-clinical-development-program-for-ksq-001ex-a-crispr-cas9-engineered-tumor-infiltrating-lymphocyte-etil-therapy\/","title":{"rendered":"KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR\/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL\u00ae<\/sup>) Therapy"},"content":{"rendered":"

Lexington, Mass., June 12, 2024<\/strong>\u00a0\u2014\u00a0<\/strong>KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1\/2 clinical study of KSQ-001EX, a novel edited TIL therapy. KSQ-001EX consists of TIL in which the SOCS1 gene is inactivated by CRISPR\/Cas9 gene editing, giving it the potential to be a best-in-class treatment for a variety of solid tumor indications. KSQ\u2019s CRISPRomics\u00ae<\/sup>\u00a0platform identified SOCS1 as a key gene inhibiting T cell growth, survival, and differentiation by negatively regulating cytokine signaling in the tumor microenvironment.<\/p>\n

\u201cTIL have emerged as a powerful new treatment modality, and we believe both of our eTIL\u00ae<\/sup> programs, KSQ-001EX and KSQ-004EX, have the potential to significantly advance the field by improving the potency of TIL therapy for the treatment of a variety of solid tumor types. In preclinical studies, KSQ-001EX demonstrated enhanced anti-tumor activity, polyclonality, persistence, and memory formation in multiple solid tumor models compared to unmodified TIL. We also saw robust anti-tumor activity in models insensitive to PD-1 inhibition,\u201d said Qasim Rizvi, Chief Executive Officer of KSQ. \u201cWe look forward to evaluating KSQ-001EX in patients with difficult-to-treat solid tumors, including melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.\u201d<\/p>\n

The first patient treated with KSQ-001EX was enrolled by\u00a0Rodabe Amaria, M.D.<\/a>, professor of Melanoma Medical Oncology and principal investigator of the study at The University of Texas MD Anderson Cancer Center.<\/p>\n

Phase 1\/2 Trial Design<\/strong><\/p>\n

The Phase 1\/2 clinical trial is an open-label, safety lead-in study for patients with melanoma, head and neck squamous cell carcinoma (HNSCC), and non-small cell lung cancer (NSCLC). The primary objective of the Phase 1 portion of the trial is to evaluate the safety and tolerability of KSQ-001EX. In the safety lead-in portion, a cohort of patients will be initially dosed without IL-2. The primary objective of Phase 2 is to evaluate antitumor activity in indication-specific cohorts.<\/p>\n

About KSQ-001EX<\/strong><\/p>\n

KSQ\u2019s lead eTIL\u00ae<\/sup>\u00a0cell therapy program, KSQ-001EX, in which TIL are edited to inactivate the SOCS1 gene, has the potential to revolutionize the treatment of solid tumors. In preclinical studies, KSQ-001EX demonstrated enhanced anti-tumor function in solid tumor models refractory to PD-1 inhibition, as well as enhanced persistence and memory formation.<\/p>\n

About KSQ Therapeutics<\/strong><\/p>\n

KSQ Therapeutics is advancing a pipeline of novel drug candidates to treat cancer across multiple drug modalities, including targeted therapies, adoptive cell therapies, and immunotherapies. KSQ\u2019s proprietary CRISPRomics\u00ae<\/sup>\u00a0discovery engine enables genome-scale insights driving novel therapeutic discovery. For more information, please visit the company\u2019s website at\u00a0www.ksqtx.com<\/a>.<\/p>\n

Media Contact:<\/strong>
\nCory Tromblee
\ncory@scientpr.<\/a>com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Lexington, Mass., June 12, 2024\u00a0\u2014\u00a0KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1\/2 clinical study of KSQ-001EX, a novel edited TIL therapy. KSQ-001EX consists of TIL in which the SOCS1 gene is inactivated by CRISPR\/Cas9 gene editing, giving it the potential […]<\/p>\n","protected":false},"featured_media":0,"menu_order":1,"template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false},"categories":[],"tags":[],"class_list":["post-2890","press_release","type-press_release","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/press_release\/2890","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/types\/press_release"}],"wp:attachment":[{"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/media?parent=2890"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/categories?post=2890"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/s2.designcostaging.com\/clients\/ksqtherapeutics\/wp-json\/wp\/v2\/tags?post=2890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}